

Marco Fornaro

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8002745/marco-fornaro-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31 papers	234 citations	8 h-index	14 g-index
47 ext. papers	407 ext. citations	3.4 avg, IF	3.25 L-index

#	Paper	IF	Citations
31	Safety profile and low risk of disease relapse after BNT162b2 mRNA SARS-COV-2 vaccination in patients with rare rheumatic diseases.. <i>Journal of Rheumatology</i> , 2022 ,	4.1	1
30	Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors.. <i>RMD Open</i> , 2022 , 8,	5.9	2
29	Complete Hydatidiform Mole Mimicking Sacroiliitis. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, e122	1.1	2
28	Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis. <i>Rheumatology</i> , 2021 , 60, 2916-2926	3.9	5
27	Predictors of long-term clinical remission in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13363	4.6	2
26	Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis. <i>Rheumatology</i> , 2021 , 60, 1234-1242	3.9	3
25	Histopathologic Features of Fibrotic Knee Synovitis in a Young Adult With Seronegative Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, e73-e74	1.1	2
24	A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents. <i>Journal of Clinical Rheumatology</i> , 2021 ,	1.1	7
23	The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment. <i>Trends in Cardiovascular Medicine</i> , 2021 , 31, 265-274	6.9	9
22	Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study. <i>Vaccines</i> , 2021 , 9,	5.3	12
21	Body mass index and adipokines/cytokines dysregulation in systemic sclerosis. <i>Clinical and Experimental Immunology</i> , 2021 , 206, 153-160	6.2	2
20	Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection. <i>Internal and Emergency Medicine</i> , 2021 , 1	3.7	0
19	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020 , 7, 42	4.9	6
18	Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is highly expressed in CD14+ circulating cells of scleroderma patients. <i>Rheumatology</i> , 2020 , 59, 1442-1444	3.9	0
17	The Impact of Biologic Drugs on High-Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients. <i>Journal of Clinical Rheumatology</i> , 2020 , Publish Ahead of Print,	1.1	2
16	Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. <i>Rheumatology</i> , 2020 , 59, 1599-1606	3.9	15
15	Paradoxical Pustular Psoriasis in a Patient With Psoriatic Arthritis on Secukinumab Treatment. <i>Journal of Clinical Rheumatology</i> , 2020 , 26, e208-e209	1.1	2

14	Symmetrical Panniculitis in a Patient With Dermatomyositis: An Unusual Onset. <i>Journal of Clinical Rheumatology</i> , 2020 , 26, e311	1.1	0
13	Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13343	4.6	1
12	Effectiveness and safety of secukinumab in patients with moderate-severe psoriasis: A multicenter real-life study. <i>Dermatologic Therapy</i> , 2020 , 33, e14044	2.2	3
11	Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e104	2.4	3
10	Response to: "Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients" by Fornaro Uby Agca. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e106	2.4	
9	Thrombocytopenia in idiopathic inflammatory myopathies: a case series analysis. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 891-895	2.2	0
8	A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019 , 38, 1309-1317	3.9	9
7	Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	41
6	Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE). <i>Reumatismo</i> , 2019 , 71, 24-30	1.1	2
5	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	48
4	Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. <i>Rheumatology</i> , 2019 ,	3.9	3
3	Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCl) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings. <i>European Journal of Clinical Investigation</i> , 2018 , 48, e12912	4.6	28
2	Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. <i>Mediators of Inflammation</i> , 2018 , 2018, 2453265	4.3	21
1	AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 911.1-911.4		